Edwards Lifesciences Corp: Form 10-Q for the period ended Jun 30, 2019
Filed with the SEC on Jul 26, 2019 and accepted by EDGAR at Jul 26, 2019, 16:05 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2019-04-01 to 2019-06-30 | $1.09bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2019-01-01 to 2019-06-30 | $2.08bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2019-04-01 to 2019-06-30 | $304.0m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2019-01-01 to 2019-06-30 | $535.8m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2019-04-01 to 2019-06-30 | $782.9m | us-gaap:GrossProfit |
| Gross profit | 6 months2019-01-01 to 2019-06-30 | $1.54bn | us-gaap:GrossProfit |
| Research and development | 3 months2019-04-01 to 2019-06-30 | $191.9m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2019-01-01 to 2019-06-30 | $363.3m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2019-04-01 to 2019-06-30 | $308.5m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2019-01-01 to 2019-06-30 | $588.8m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2019-04-01 to 2019-06-30 | $267.5m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2019-01-01 to 2019-06-30 | $541.7m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2019-04-01 to 2019-06-30 | $29.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2019-01-01 to 2019-06-30 | $57.3m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2019-04-01 to 2019-06-30 | $242.3m | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
| Net income | 6 months2019-01-01 to 2019-06-30 | $492.0m | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
| Diluted EPS | 3 months2019-04-01 to 2019-06-30 | $1.14 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2019-01-01 to 2019-06-30 | $2.32 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2019-04-01 to 2019-06-30 | $1.16 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2019-01-01 to 2019-06-30 | $2.37 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2019-04-01 to 2019-06-30 | 212,100,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2019-01-01 to 2019-06-30 | 212,100,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2019-01-01 to 2019-06-30 | $342.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2019-01-01 to 2019-06-30 | $106.8m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 6 months2019-01-01 to 2019-06-30 | $262.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2019-06-30 | $726.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2019-06-30 | $2.35bn | us-gaap:AssetsCurrent |
| Total assets | At period end2019-06-30 | $5.57bn | us-gaap:Assets |
| Current liabilities | At period end2019-06-30 | $697.0m | us-gaap:LiabilitiesCurrent |
| Long-term debt | At period end2019-06-30 | $594.1m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | At period end2019-06-30 | $3.50bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001099800-19-000019. Last ingested by Listed: Nov 15, 2026, 03:19 ET. Listed shows no prices and gives no investment advice.